Drug Trial Radar · NCT05838066
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Jul 23, 2023
Primary completion
Jul 31, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).
Conditions
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Interventions
Recombinant Humanized Bispecific antibody against HER2,KN026Drug
IV infusion
HB1801Drug
IV infusion
PertuzumabDrug
840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
TrastuzumabDrug
8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
DocetaxelDrug
75 mg/m\^2, D1 Q3W, IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).Time frame: Up to approximately 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Beijing, chaoyang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.